XBiotech (NASDAQ:XBIT) announces the launch of a new breakthrough candidate therapy called FLUVID for treating illness caused by combined infections with influenza and COVID-19.
FLUVID therapy will combine XBiotech’s breakthrough influenza True Human antibodies together with its recently discovered COVID-19 antibodies into one treatment and will be used to provide immunity to infection or to treat infections once they have occurred.
https://seekingalpha.com/news/3615659-xbiotech-launches-new-influenza-covidminus-19-antibody-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.